752 related articles for article (PubMed ID: 25991002)
1. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
Carvajal-Hausdorf DE; Schalper KA; Pusztai L; Psyrri A; Kalogeras KT; Kotoula V; Fountzilas G; Rimm DL
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25991002
[TBL] [Abstract][Full Text] [Related]
2. Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
Carvajal-Hausdorf DE; Schalper KA; Bai Y; Black J; Santin AD; Rimm DL
Gynecol Oncol; 2017 Apr; 145(1):154-158. PubMed ID: 28196634
[TBL] [Abstract][Full Text] [Related]
3. In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.
Vassilakopoulou M; Togun T; Dafni U; Cheng H; Bordeaux J; Neumeister VM; Bobos M; Pentheroudakis G; Skarlos DV; Pectasides D; Kotoula V; Fountzilas G; Rimm DL; Psyrri A
PLoS One; 2014; 9(6):e99131. PubMed ID: 24968015
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
5. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
6. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
[TBL] [Abstract][Full Text] [Related]
7. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer.
Murthy RK; Varma A; Mishra P; Hess KR; Young E; Murray JL; Koenig KH; Moulder SL; Melhem-Bertrandt A; Giordano SH; Booser D; Valero V; Hortobagyi GN; Esteva FJ
Cancer; 2014 Jul; 120(13):1932-8. PubMed ID: 24677057
[TBL] [Abstract][Full Text] [Related]
8. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
[TBL] [Abstract][Full Text] [Related]
9. Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.
Sonnenblick A; Brohée S; Fumagalli D; Rothé F; Vincent D; Ignatiadis M; Desmedt C; Salgado R; Sirtaine N; Loi S; Neven P; Loibl S; Denkert C; Joensuu H; Piccart M; Sotiriou C
Oncotarget; 2015 Oct; 6(30):30306-16. PubMed ID: 26358523
[TBL] [Abstract][Full Text] [Related]
10. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
[TBL] [Abstract][Full Text] [Related]
11. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
de Nonneville A; Gonçalves A; Zemmour C; Classe JM; Cohen M; Lambaudie E; Reyal F; Scherer C; Muracciole X; Colombo PE; Giard S; Rouzier R; Villet R; Chopin N; Darai E; Garbay JR; Gimbergues P; Sabiani L; Coutant C; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
Breast Cancer Res Treat; 2017 Apr; 162(2):307-316. PubMed ID: 28155054
[TBL] [Abstract][Full Text] [Related]
12. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
[TBL] [Abstract][Full Text] [Related]
13. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.
Perez EA; Thompson EA; Ballman KV; Anderson SK; Asmann YW; Kalari KR; Eckel-Passow JE; Dueck AC; Tenner KS; Jen J; Fan JB; Geiger XJ; McCullough AE; Chen B; Jenkins RB; Sledge GW; Winer EP; Gralow JR; Reinholz MM
J Clin Oncol; 2015 Mar; 33(7):701-8. PubMed ID: 25605861
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.
Zhou J; Peng Z; Liu Y; Gong J; Zhang X; Lu M; Gao J; Li Y; Li Y; Shen L
J Gastroenterol; 2015 Sep; 50(9):955-61. PubMed ID: 25702260
[TBL] [Abstract][Full Text] [Related]
15. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831.
Crozier JA; Moreno-Aspitia A; Ballman KV; Dueck AC; Pockaj BA; Perez EA
Cancer; 2013 Jul; 119(13):2447-54. PubMed ID: 23585192
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
17. Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain.
Knutson KL; Clynes R; Shreeder B; Yeramian P; Kemp KP; Ballman K; Tenner KS; Erskine CL; Norton N; Northfelt D; Tan W; Calfa C; Pegram M; Mittendorf EA; Perez EA
Cancer Res; 2016 Jul; 76(13):3702-10. PubMed ID: 27197192
[TBL] [Abstract][Full Text] [Related]
18. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice.
Bonifazi M; Franchi M; Rossi M; Zambelli A; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
Breast; 2014 Oct; 23(5):573-8. PubMed ID: 24934637
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
